BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Meiji Seika Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Meiji Seika Pharma's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04643002-1886@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Belumosudil: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Belumosudil\, phase 1/2.\nStudy: Isatuximab in Combination With
  Novel Agents in RRMM - Master Protocol\nEstimated primary completion: 13 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belum
 osudil#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04643002
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2286@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Chidamide: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Chidamide\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 idinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Color
 ectal Cancer Patients\nEstimated primary completion: 31 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116031-1886@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Belumosudil: Phase 2 readout est. (NCT07116031)
DESCRIPTION:Belumosudil\, phase 2\, Graft-versus-Host Disease.\nStudy: A St
 udy of Belumosudil in Children With Chronic Graft Versus Host Disease (sch
 oolROCK)\nEstimated primary completion: 25 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/belumosudil#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07116031
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143891-1886@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06143891)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Test an Oral Medicine\, Belumosudil\, in Combination With Corticost
 eroids in Participants at Least 12 Years of Age With Newly Diagnosed Chron
 ic Graft Versus Host Disease.\nEstimated primary completion: 29 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614389
 1
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082037-1886@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Belumosudil: Phase 3 readout est. (NCT06082037)
DESCRIPTION:Belumosudil\, phase 3.\nStudy: A Study to Test How Effective Be
 lumosudil Tablets Are for Treating Adult Participants With Chronic Lung Al
 lograft Dysfunction\nEstimated primary completion: 29 January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06082037
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771439-1886@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Belumosudil: Phase 3 readout est. (NCT07771439)
DESCRIPTION:Belumosudil\, phase 3\, Graft-versus-Host Disease.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Belumosudil Compared With Be
 st Available Therapy in Participants Aged 12 Years or Older With Chronic G
 raft-versus-host Disease\nEstimated primary completion: 14 September 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/belumosudil#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07771439
URL:https://assetmemo.bio/drug/belumosudil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947967-2286@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06947967)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: Tucid
 inostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymp
 homa With Follicular Helper of T Cell Phenotype\nEstimated primary complet
 ion: December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06947967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
